- Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion.
- The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall.
- Adjusted EPS decreased 34% to $0.33, as higher sales volumes, increased pricing, and procurement actions were more than offset by cost headwinds and unfavorable foreign exchange rate movements.
- Currency-neutral EPS was $0.37, including a $0.02 per share negative impact from the war in Ukraine.
- Guidance: Perrigo expects FY22 sales growth of 8.5% - 9.5% compared to the previous outlook of 3.5% to 4.5%.
- It sees sales of $4.49 billion - $4.53 billion, beating the consensus of $4.49 billion.
- It expects organic sales growth of 8% - 9% up from 7.0% - 8.0% expected earlier.
- The company expects adjusted EPS of $2.30-$2.40, up from $2.10 - $2.30, reflecting approximately $0.35 from the HRA acquisition, offset by $0.10 from the unfavorable exchange rate, $0.05 Russia impact, and around $0.05 in higher interest expense.
- Price Action: PRGO shares are up 5.52% at $34.11 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Perrigo Shares Pop On Raised FY22 Guidance Surpassing Consensus Estimates
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks